Skip to main content
. Author manuscript; available in PMC: 2009 Jul 15.
Published in final edited form as: Clin Cancer Res. 2008 Jul 15;14(14):4526–4531. doi: 10.1158/1078-0432.CCR-07-5048

Table 2.

Survival of patients receiving vaccine or hormone therapy or both at PSA progression, from on-study date.

Initial randomization 3-year survival Median OS
Vaccine (V) 81% 5.1 yrs
Nilutamide 62% 3.4 yrs
Crossover at progression
V then V + N 100% 6.2 yrs
N then N + V 75% 3.7 yrs